Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

IBRX

ImmunityBio Inc

Jan 16 • 12:22PM ET

5.37

+1.42 35.95 %

Healthcare • Biotechnology • USA • NASD

Peers: MRNA BNTX NVAX PFE VRTX REGN GILD ALNY AMGN BIIB

| Held by: XBI VTI IWM VB IBB VBK IWO VXF SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.42	Insider Own	66.42%	Shs Outstand	984.97M	Perf Week	130.47%
Market Cap	5.29B	Forward P/E	-	EPS next Y	-0.29	Insider Trans	0.00%	Shs Float	330.75M	Perf Month	148.61%
Enterprise Value	5.89B	PEG	-	EPS next Q	-0.09	Inst Own	14.62%	Short Float	36.48%	Perf Quarter	112.25%
Income	-348.62M	P/S	64.07	EPS this Y	34.64%	Inst Trans	6.13%	Short Ratio	9.18	Perf Half Y	95.27%
Sales	82.56M	P/B	-	EPS next Y	27.77%	ROA	-78.91%	Short Interest	120.64M	Perf YTD	171.21%
Book/sh	-0.53	P/C	20.52	EPS next 5Y	-	ROE	-	52W High	4.27 25.76%	Perf Year	124.69%
Cash/sh	0.26	P/FCF	-	EPS past 3/5Y	11.44% 2.39%	ROIC	-106.61%	52W Low	1.83 193.44%	Perf 3Y	20.95%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	150.86% 221.39%	Gross Margin	80.41%	Volatility	14.23% 7.14%	Perf 5Y	-62.55%
Dividend TTM	-	EV/Sales	71.39	EPS Y/Y TTM	52.91%	Oper. Margin	-315.84%	ATR (14)	0.32	Perf 10Y	-61.03%
Dividend Ex-Date	-	Quick Ratio	5.65	Sales Y/Y TTM	1025.95%	Profit Margin	-422.28%	RSI (14)	92.25	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.77	EPS Q/Q	50.56%	SMA20	116.62%	Beta	0.01	Target Price	10.40
Payout	-	Debt/Eq	-	Sales Q/Q	425.07%	SMA50	134.48%	Rel Volume	20.37	Prev Close	3.95
Employees	680	LT Debt/Eq	-	Earnings	Nov 05 BMO	SMA200	112.96%	Avg Volume	13.14M	Price	5.37
IPO	Jul 28, 2015	Option/Short	Yes / No	EPS/Sales Surpr.	34.64% 0.57%	Trades		Volume	125,542,014	Change	35.95%

Date	Action	Analyst	Rating Change	Price Target Change
May-20-25	Upgrade	Piper Sandler	Neutral → Overweight	$5
Mar-06-25	Initiated	H.C. Wainwright	Buy	$8
Jan-10-25	Initiated	BTIG Research	Buy	$6
May-12-23	Downgrade	Piper Sandler	Overweight → Neutral	$10 → $4
Aug-03-22	Initiated	Jefferies	Buy	$8

Today 11:33AM	ImmunityBio (IBRX) Extends Gains to 10th Day on 700% Anktiva Sales Jump; Time to Book Profits? (Insider Monkey) +35.95%
11:04AM	ImmunityBio's 700% Revenue Boom Becomes Citadel's Latest I-Told-You-So (Benzinga)
10:41AM	Looking For A Short Squeeze? 10 Stocks Ready To Rocket (Benzinga)
10:22AM	These Stocks Are Todays Movers: Micron, Sandisk, AST SpaceMobile, Constellation Energy, Novo Nordisk, and More (Barrons.com)
09:40AM	This Biotech Stock Is Up More Than 100% This Year. Why Its Soaring Again Today. (Barrons.com)
09:27AM	Loading…
09:27AM	Ford & BYD reportedly in talks to partner, PNC rises on earnings (Yahoo Finance Video)
08:27AM	Micro shares surge on share buying by board member, and more stocks on the move (MarketWatch)
08:00AM	IRS Proposes Tax Changes That Could Target Sovereign Wealth Funds' US Investments: Report (Benzinga)
08:00AM	Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape (PR Newswire)
07:00AM	ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma (Business Wire)
07:00AM	ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA Plus BCG (Business Wire)
05:53AM	These Stocks Are Today's Movers: Micron, Sandisk, J.B. Hunt, HP Inc., ImmunityBio, and More (Barrons.com)
05:52AM	This Biotech Stock Is Up 100% This Year. Why It's Soaring Again Today. (Barrons.com)
05:46AM	Stock Market Today: Dow Jones, S&P 500 Futures Gain Following Stellar Chipmaker Rally-Chevron, Paysafe, J.B. Hunt Transport In Focus (Benzinga)
Jan-15-26 08:26PM	Robinhood, TSMC, Reddit, ImmunityBio And AST Spacemobile: Why These 5 Stocks Are On Investors' Radars Today (Benzinga) +30.79%
12:43PM	Loading…
12:43PM	ImmunityBio Clocks 700% Revenue Surge In 2025 From Lead Bladder Cancer Drug (Benzinga)
08:30AM	ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue-a 700% increase year-over-year (Business Wire)
Jan-14-26 02:13PM	H.C Wainwright Asserts Buy Stance as ImmunityBio, Inc. (IBRX) Achieves Positive Results on Bladder Cancer Treatment (Insider Monkey) +7.09%
09:15AM	ImmunityBio announces results from Anktiva clinical program (TipRanks)
08:30AM	Saudi FDA Grants Accelerated Approval to ImmunityBios ANKTIVA In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer (Business Wire)
08:30AM	Saudi FDA Grants Accelerated Approval to ImmunityBios ANKTIVA for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ (Business Wire)
07:10AM	ImmunityBio (IBRX) Extends Rally on 8th Day on Strong Clinical Trial Results (Insider Monkey)
Jan-13-26 08:30AM	ImmunityBio Announces Positive Results Demonstrating ANKTIVA as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer (Business Wire) +8.88%
Jan-12-26 08:30AM	NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit to Advance Immunotherapy 2.0 and Global Health Security (Business Wire) +11.16%
Dec-29-25 10:15AM	3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround (Zacks)
09:00AM	ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of 100 Most Influential People in Oncology in 2025 (Business Wire)
Dec-18-25 10:40AM	3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment (Zacks)
05:23AM	Is ImmunityBio, Inc. (IBRX) The Best NASDAQ Stock Under $10 to Buy? (Insider Monkey)
01:14AM	Jefferies Lifts ImmunityBio Inc. (IBRX) Price Target Following Anktiva European Expansion (Insider Monkey)
Dec-16-25 09:00AM	ANKTIVA with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer (Business Wire)
07:15AM	Loading…
Dec-13-25 07:15AM	ImmunityBio (IBRX) Climbs 7.76% on Europe Expansion (Insider Monkey)
Dec-12-25 06:10AM	ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ-A First in Europe (Business Wire) +7.76%
Dec-05-25 03:06PM	ImmunityBio, Inc. (IBRX): A Bull Case Theory (Insider Monkey)
Dec-03-25 11:08AM	ImmunityBio (IBRX) Slashes 9% on Lack of Leads (Insider Monkey) +5.26%
Dec-01-25 09:10AM	ImmunityBio (IBRX) Soars 10.8% Ahead of Health Conferences (Insider Monkey)
Nov-30-25 05:38AM	Is ImmunityBio Inc. (IBRX) The Best US Stock To Buy Under $20? (Insider Monkey)
Nov-24-25 09:47AM	H.C. Wainwright Asserts Buy Rating on Immunitybio Inc. (IBRX) as Net Loss Narrows on Robust Product Revenue (Insider Monkey)
Nov-13-25 09:00AM	New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations (Business Wire)
Nov-05-25 05:05AM	ImmunityBio: Q3 Earnings Snapshot (Associated Press Finance)
Nov-04-25 10:12PM	Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024 (Business Wire) -7.96%
Nov-03-25 05:40PM	Myriad Genetics (MYGN) Reports Break-Even Earnings for Q3 (Zacks) -5.83%
Oct-01-25 01:45PM	ImmunityBio, Inc. (IBRX) Reports Strong Q2 Growth, Eyes Lung Cancer and NMIBC Expansion (Insider Monkey)
Sep-30-25 02:49PM	Wall Street Bullish on ImmunityBio (IBRX) Since the Announcement of New Findings From QUILT-3.055 Study (Insider Monkey)
Sep-20-25 02:43AM	ImmunityBio's (IBRX) ANKTIVA Shows Survival Gains in Lung Cancer Patients (Insider Monkey)
Sep-17-25 06:22PM	Biotech Breakouts: 3 Stocks With Massive Upside Potential (MarketBeat)
Sep-16-25 12:29PM	Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals (PR Newswire)
Sep-15-25 08:17AM	H.C. Wainwright Reiterates Buy Rating on ImmunityBio, Keeps PT at $8 (Insider Monkey) +5.38%
Sep-08-25 08:30AM	ImmunityBio's ANKTIVA Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy (Business Wire)
Aug-31-25 12:17AM	ImmunityBio (IBRX) Reports Initial Study Data Showing 100% Disease Control in Patients With Recurrent Glioblastoma (Insider Monkey)
Aug-28-25 10:44AM	FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone (PR Newswire)
05:04AM	ImmunityBio, Inc. (IBRX) Targets Lymphopenia with Cancer BioShield Platform (Insider Monkey)
Aug-26-25 08:30AM	Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio's ANKTIVA, NK Cell Therapy Plus Optune Gio Device (Business Wire) +5.78%
Aug-19-25 08:30AM	ImmunityBio Announces Phase 2 Study of ANKTIVA in Patients with Long COVID (Business Wire) -6.17%
Aug-17-25 05:58PM	ImmunityBio (IBRX) Reports 60% Revenue Growth as ANKTIVA Adoption Accelerates (Insider Monkey)
Aug-14-25 01:46PM	ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results (Insider Monkey)
Aug-13-25 08:30AM	ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy (Business Wire) +14.17%
Aug-11-25 08:30AM	ImmunityBio Announces Houston's Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA to Bladder Cancer Patients (Business Wire)
Aug-05-25 08:20AM	ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:17AM	ImmunityBio: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code (Business Wire)
Aug-04-25 10:01AM	ImmunityBio (IBRX) Announces Preliminary Financial Results for the Quarter Ended June 30 (Insider Monkey)
Aug-01-25 06:47AM	Immunitybio (IBRX) Targets $80 Million Capital Raise for Business Operations (Insider Monkey)
Jul-31-25 11:34AM	ImmunityBio, Inc. (IBRX) Gains UK Approval for ANKTIVA in Bladder Cancer (Insider Monkey)
Jul-25-25 06:03AM	ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors (Business Wire)
06:00AM	ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates (Business Wire)
Jul-23-25 11:25AM	ImmunityBio's (IBRX) ANKTIVA Gets Approved by UK's Medicines and Healthcare Regulatory Agency (Insider Monkey) +10.33%
Jul-09-25 08:30AM	Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers (PR Newswire)
Jul-07-25 09:43PM	UK MHRA Approves ImmunityBio's ANKTIVA Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ (Business Wire)
09:10AM	Bullish Sentiments for ImmunityBio (IBRX) After Trial Success and FDA Authorization (Insider Monkey)
Jul-02-25 02:47AM	ImmunityBio (IBRX) Rated Buy After FDA Approvals and Pancreatic Cancer Trial Success (Insider Monkey)
Jun-24-25 03:51PM	ImmunityBio (IBRX) Attains FDA's Expanded Access Authorization for its Cancer BioShield Platform Anchored by ANKTIVA (Insider Monkey)
Jun-12-25 10:00AM	As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry (PR Newswire)
Jun-04-25 11:56PM	Why ImmunityBio, Inc. (IBRX) Skyrocketed Today (Insider Monkey) +8.12%
Jun-03-25 09:25AM	ImmunityBio receives FDA Expanded Access authorization for Cancer BioShield (TipRanks)
08:45AM	ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer (Business Wire)
Jun-02-25 09:00AM	ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA, the Cancer BioShield Platform, in Patients With Solid Tumors (Business Wire)
May-27-25 08:00AM	ImmunityBio, Saudi Arabias Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield Platform in the Middle East (Business Wire)
May-22-25 08:46AM	CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success (Zacks)
06:00AM	Piper Sandler Upgrades ImmunityBio (IBRX) to Overweight, Lifts PT (Insider Monkey)
May-21-25 08:31PM	Why ImmunityBio, Inc. (IBRX) Crashed Today (Insider Monkey) -8.62%
May-20-25 08:59PM	Jim Cramer Notes ImmunityBio (IBRX) Has "Been Losing Money Forever" (Insider Monkey)
12:43PM	Why ImmunityBio, Inc. (IBRX) Surged Last Week (Insider Monkey)
May-19-25 08:30PM	Lightning Round: Zoom is doing a lot right, but it's taking them a really long time, says Jim Cramer (CNBC TV)
May-15-25 12:00PM	ImmunityBio (IBRX) Moves to Buy: Rationale Behind the Upgrade (Zacks) +7.23%
May-12-25 11:12PM	Why ImmunityBio, Inc. (IBRX) Soared Today (Insider Monkey) +14.01% +6.36%
07:35AM	ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:30AM	ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code (Business Wire)
May-09-25 08:30AM	Is ImmunityBio, Inc. (IBRX) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-06-25 10:00AM	Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
May-05-25 05:05PM	ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA (Seeking Alpha) -17.32%
06:30AM	ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agencys Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025 (Business Wire)
May-01-25 10:01AM	ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-29-25 12:50PM	ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish (Seeking Alpha) -5.32%
Apr-28-25 08:30AM	Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone Best in Disease and Best in Class with 5 Year Follow-Up (Business Wire)
Apr-21-25 04:21PM	ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting (Business Wire) +7.17%
Apr-17-25 12:05AM	Why ImmunityBio, Inc. (IBRX) Declined on Wednesday (Insider Monkey)
Apr-15-25 08:00AM	ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA to Treat Lymphopenia (Business Wire)
12:40AM	Why ImmunityBio Inc. (IBRX) Skyrocketed On Monday? (Insider Monkey)
Apr-09-25 09:42AM	ImmunityBio, Inc. (IBRX): Among Stocks Under $10 that Will Triple (Insider Monkey) +7.44%
06:16AM	Why ImmunityBio Inc. (IBRX) Went Down On Tuesday? (Insider Monkey)

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sachs David C.	Chief Financial Officer	Dec 31 '25	Option Exercise	0.00	30,397	0	256,017	Jan 05 06:11 PM
Adcock Richard	CEO & President	Dec 31 '25	Option Exercise	0.00	34,483	0	368,901	Jan 05 06:10 PM
LAUER REGAN J	Chief Accounting Officer	Feb 22 '25	Option Exercise	0.00	4,065	0	111,927	Feb 25 09:11 PM
SOON-SHIONG PATRICK	See remarks	Feb 22 '25	Option Exercise	0.00	114,329	0	29,588,261	Feb 25 09:11 PM
Sachs David C.	Chief Financial Officer	Feb 22 '25	Option Exercise	0.00	40,650	0	241,480	Feb 25 09:11 PM
Adcock Richard	CEO & President	Feb 22 '25	Option Exercise	0.00	152,439	0	412,585	Feb 25 09:11 PM
Simon Barry J.	Director	Feb 22 '25	Option Exercise	0.00	15,243	0	3,249,024	Feb 25 09:11 PM
Simon Barry J.	Director	Jan 22 '25	Option Exercise	2.00	110,020	219,864	3,233,781	Jan 24 08:47 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IBRX

ImmunityBio Inc

Upgrade your FINVIZ experience